BOLT (Bolt Biotherapeutics) Loans Receivable: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOLT Bolt Biotherapeutics Inc BOLT
53 GF Score
Price $4.21
GF Value $9.07
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Bolt Biotherapeutics Loans Receivable?

Bolt Biotherapeutics BOLT +2.68% 53 Loans Receivable is $0.00 Mil as of Mar. 2026. GuruFocus rates BOLT with a GF Score™ of 53/100 and a GF Value™ of $9.07 (Possible Value Trap). The stock has 4 warning signs investors should review.

Bolt Biotherapeutics's Loans Receivable for the quarter that ended in Mar. 2026 was $0.00 Mil.

Bolt Biotherapeutics Loans Receivable Related Terms

Bolt Biotherapeutics Loans Receivable Historical Data

* Premium members only.

The historical data trend for Bolt Biotherapeutics's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bolt Biotherapeutics Loans Receivable Chart

Bolt Biotherapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Bolt Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOLT
53GF Score
Bolt Biotherapeutics Inc BOLT
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bolt Biotherapeutics Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of $0.00 Mil mean?
Bolt Biotherapeutics (BOLT) has a Loans Receivable of $0.00 Mil as of Mar. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Bolt Biotherapeutics and its competitors.
Is Bolt Biotherapeutics' Loans Receivable too high?
Bolt Biotherapeutics' current Loans Receivable is $0.00 Mil. Overall, Bolt Biotherapeutics has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bolt Biotherapeutics' Loans Receivable compare to AIM and ERNA?
Bolt Biotherapeutics' Loans Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Biotechnology company?
A good Loans Receivable depends on the Biotechnology industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Bolt Biotherapeutics and its competitors. Bolt Biotherapeutics's current Loans Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bolt Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Bolt Biotherapeutics (BOLT) is currently considered Possible Value Trap. The stock's GF Value™ is $9.07, compared to a current price of $4.21 — trading 53.6% below its estimated fair value. The current Loans Receivable is $0.00 Mil. Bolt Biotherapeutics' overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Bolt Biotherapeutics (BOLT), the current Loans Receivable is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bolt Biotherapeutics (BOLT) Overvalued in 2026?

Based on GuruFocus' analysis, Bolt Biotherapeutics stock appears to be undervalued. The current stock price of $4.21 is trading 53.6% below its estimated GF Value™ of $9.07. GuruFocus considers Bolt Biotherapeutics to be Possible Value Trap.

Key valuation signals for BOLT:

  • Loans Receivable: $0.00 Mil
  • GF Value™: $9.07 vs. price of $4.21 (53.6% below fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the BOLT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bolt Biotherapeutics Business Description

Address 900 Chesapeake Drive, Redwood City, CA, USA, 94063
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
53GF Score

Get the complete analysis for BOLT

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.21
Price
$9.07
GF Value